Skip to main content
GH

Guoyan Hanyin

Guoyan Hanyin develops ultra-sensitive molecular diagnostic solutions for precise quantification of low-abundance protein biomarkers. Their proprietary microfluidic chip platform enables single-molecule immunoassay analysis, offering over 1000x greater sensitivity than traditional methods for early disease detection and precision medicine applications.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Traditional diagnostic methods for detecting low-abundance protein biomarkers often lack the sensitivity and precision required for early disease detection and personalized treatment strategies. This limitation hinders the advancement of precision medicine, particularly in complex fields like oncology and neurodegenerative diseases.

Solution

Guoyan Hanyin develops and commercializes advanced molecular diagnostic medical products designed to overcome the sensitivity limitations of conventional assays. The company's core technology is a proprietary microfluidic chip platform integrated with opto-mechanical-electrical modules. This platform enables single-molecule immunoassay analysis, achieving detection sensitivities significantly exceeding traditional methods like ELISA and chemiluminescence. By facilitating the precise quantification of low-abundance protein biomarkers directly from various sample types, Guoyan Hanyin's solutions aim to enhance diagnostic accuracy and support the progression of precision medicine.

Target Audience

The primary customers are clinical laboratories, research institutions, and pharmaceutical companies engaged in diagnostics, drug discovery, and personalized medicine.

Features

  • Microfluidic chip platform for single-molecule immunoassay analysis.
  • Integrated opto-mechanical-electrical modules for enhanced assay performance.
  • Detection sensitivity exceeding traditional ELISA and chemiluminescence by over 1000x.
  • Direct quantification of low-abundance protein biomarkers in serum and plasma.
  • Achieves a detection limit as low as 1 fg/mL for ultra-sensitive biomarker measurement.
  • Supports high-throughput, continuous sample processing for research and clinical applications.
  • Applicable to a range of diagnostic areas including oncology, neurodegenerative diseases, cardiovascular diseases, and infectious diseases.
  • Offers both single-molecule immunoassay analyzers and corresponding reagent kits.
This profile is AI-generated and may contain inaccuracies.